Macro Group Pharmaceutical (Macro Capital) has garnered a consolidated net profit attributable to the parent company worth EGP 103.88 million during the first nine months of 2025, versus net losses amounting to EGP 66.119 million in the same period a year earlier, according to financial statements filed to the Egyptian Exchange (EGX) on November 13th.

The extraordinary general meeting (EGM) agreed to increase the authorized capital of Macro Group Pharmaceutical (Macro Capital) to EGP 3 billion from EGP 575 million

Macro Group Pharmaceutical (Macro Capital) generated consolidated net profits attributable to the parent amounting to EGP 68.911 million in the first half (H1) of 2025, against net losses of EGP 88.795 million in H1 2024

Macro Group Pharmaceutical (Macro Capital) turned profitable with EGP 22.382 million in the first quarter (Q1) of 2025

Macro Group Pharmaceutical (Macro Capital) recorded a block-trading deal at a value of EGP 630.979 million

Macro Capital suffered 86.02%% year-on-year (YoY) lower consolidated net losses attributable to the parent company at EGP 38.098 million in 2024

Macro Group Pharmaceutical (Macro Capital) has incurred a consolidated net loss attributable to the parent company worth EGP 66.119 million during the first nine months of 2024, versus net profits amounting to EGP 98.090 million in the same period a year earlier.

Macro Group Pharmaceutical (Macro Capital) recorded EGP 88.799 million in consolidated net losses attributable to the parent company during the first half (H1) of 2024, compared to EGP 29.338 million in net profits in H1 2023.

Macro Group Pharmaceutical (Macro Capital) recorded EGP 78.112 million in consolidated net losses attributable to the parent company during the first quarter (Q1) of 2024, compared to EGP 9.445 million in net profits in H1 2023.

Macro Group Pharmaceutical (Macro Capital) has incurred EGP 272.651 million in consolidated net losses attributable to the parent company during the first quarter (Q1) of 2024, versus net profits amounting to EGP 173.835 million during the first three months of 2023, according to the consolidated financial statement filed to the Egyptian Exchange (EGX) on April 16th.

Macro Group Pharmaceutical (Macro Capital) (MCRO) posted a 24.22% year-on-year (YoY) decrease in consolidated profit attributable to the parent company during the first nine months of 2023.

Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.

Macro Group Pharmaceutical (Macro Capital) has reported a 69.2% year-on-year (YoY) decline in consolidated profits attributable to the parent company during the first quarter (Q1) of 2023.

Macro Group Pharmaceutical (Macro Capital) announced that it is targeting sales of EGP 1 billion in 2023 via maintaining the 25-30% expected growth rate this year.

Macro Group Pharmaceuticals has approved the payment of EGP 0.1067 per share in cash dividends to shareholders for 2022 over two installments.

Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.

Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.